Related references
Note: Only part of the references are listed.Cooperative Immune-Mediated Mechanisms of the HDAC Inhibitor Entinostat, an IL15 Superagonist, and a Cancer Vaccine Effectively Synergize as a Novel Cancer Therapy
Kristin C. Hicks et al.
CLINICAL CANCER RESEARCH (2020)
Clinical Development of Immunotherapy for Deficient Mismatch Repair Colorectal Cancer
Jane Thomas et al.
CLINICAL COLORECTAL CANCER (2020)
Rationale for IL-15 superagonists in cancer immunotherapy
Karin M. Knudson et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2020)
Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer
Houssein Abdul Sater et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence
Raju K. Vaddepally et al.
CANCERS (2020)
A guide to cancer immunotherapy: from T cell basic science to clinical practice
Alex D. Waldman et al.
NATURE REVIEWS IMMUNOLOGY (2020)
Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy
Karin M. Knudson et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Efficient Tumor Clearance and Diversified Immunity through Neoepitope Vaccines and Combinatorial Immunotherapy
Karin L. Lee et al.
CANCER IMMUNOLOGY RESEARCH (2019)
T Regulatory Cells and Priming the Suppressive Tumor Microenvironment
Christina M. Paluskievicz et al.
FRONTIERS IN IMMUNOLOGY (2019)
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Jerome Galon et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Jonathan J. Havel et al.
NATURE REVIEWS CANCER (2019)
Cold Tumors: A Therapeutic Challenge for Immunotherapy
Paola Bonaventura et al.
FRONTIERS IN IMMUNOLOGY (2019)
Mechanisms of resistance to immune checkpoint inhibitors
Russell W. Jenkins et al.
BRITISH JOURNAL OF CANCER (2018)
Next generation of immune checkpoint therapy in cancer: new developments and challenges
Julian A. Marin-Acevedo et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study
Franck Pages et al.
LANCET (2018)
Understanding the tumor immune microenvironment (TIME) for effective therapy
Mikhail Binnewies et al.
NATURE MEDICINE (2018)
Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
Fei Tang et al.
CELL AND BIOSCIENCE (2018)
Immunological differences between primary and metastatic breast cancer
B. Szekely et al.
ANNALS OF ONCOLOGY (2018)
Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer
Jason M. Redman et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors
Saman Maleki Vareki
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
The Role of CXCR3 and Its Chemokine Ligands in Skin Disease and Cancer
Paula T. Kuo et al.
FRONTIERS IN MEDICINE (2018)
Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery
Suzanne I. S. Mosely et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Immune-related adverse events during anticancer immunotherapy: Pathogenesis and management (Review)
Stefania Stucci et al.
ONCOLOGY LETTERS (2017)
Impact of mismatch-repair deficiency on the colorectal cancer immune microenvironment
Yingyi Zhang et al.
ONCOTARGET (2017)
Cancer vaccines: Enhanced immunogenic modulation through therapeutic combinations
Margaret E. Gatti-Mays et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2017)
Myeloid-Derived Suppressor Cells
Dmitry I. Gabrilovich
CANCER IMMUNOLOGY RESEARCH (2017)
Concurrent PD-1 Blockade Negates the Effects of OX40 Agonist Antibody in Combination Immunotherapy through Inducing T-cell Apoptosis
Rajeev K. Shrimali et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40
David J. Messenheimer et al.
CLINICAL CANCER RESEARCH (2017)
Systemic Immunity Is Required for Effective Cancer Immunotherapy
Matthew H. Spitzer et al.
CELL (2017)
Tumour-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to neoadjuvant chemotherapy of aggressive breast cancer
Y. Asano et al.
BRITISH JOURNAL OF SURGERY (2016)
Assessing Immune-Related Adverse Events of Efficacious Combination Immunotherapies in Preclinical Models of Cancer
Jing Liu et al.
CANCER RESEARCH (2016)
IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas
Peter S. Kim et al.
ONCOTARGET (2016)
The ratio of CD8(+)/FOXP3 T lymphocytes infiltrating breast tissues predicts the relapse of ductal carcinoma in situ
Michaela Semeraro et al.
ONCOIMMUNOLOGY (2016)
Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, 0X40, GITR, CD27, CD28, and ICOS
Miguel F. Sanmamed et al.
SEMINARS IN ONCOLOGY (2015)
A poxviral-based cancer vaccine targeting the transcription factor twist inhibits primary tumor growth and metastases in a model of metastatic breast cancer and improves survival in a spontaneous prostate cancer model
Anna R. Kwilas et al.
ONCOTARGET (2015)
Natural Killer Cell Immunomodulation: Targeting Activating, Inhibitory, and Co-stimulatory Receptor Signaling for Cancer Immunotherapy
Cariad Chester et al.
FRONTIERS IN IMMUNOLOGY (2015)
Vaccine-Mediated Immunotherapy Directed against a Transcription Factor Driving the Metastatic Process
Andressa Ardiani et al.
CANCER RESEARCH (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapies
Jing Liu et al.
CLINICAL & TRANSLATIONAL IMMUNOLOGY (2014)
Efficacy and Mechanism-of-Action of a Novel Superagonist Interleukin-15: Interleukin-15 Receptor αSu/Fc Fusion Complex in Syngeneic Murine Models of Multiple Myeloma
Wenxin Xu et al.
CANCER RESEARCH (2013)
Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death
James W. Hodge et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice
Rupal Ramakrishnan et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
Mojgan Ahmadzadeh et al.
BLOOD (2009)
Eradication of established tumors in mice by a combination antibody-based therapy
Tomoyasu Uno et al.
NATURE MEDICINE (2006)
Share Paper
